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Basal CHK1 activity safeguards its stability to
maintain intrinsic S-phase checkpoint functions
Jone Michelena1, Marco Gatti1, Federico Teloni1,2, Ralph Imhof1, and Matthias Altmeyer1
The DNA replication machinery frequently encounters impediments that slow replication fork progression and threaten
timely and error-free replication. The CHK1 protein kinase is essential to deal with replication stress (RS) and ensure genome
integrity and cell survival, yet how basal levels and activity of CHK1 are maintained under physiological, unstressed
conditions is not well understood. Here, we reveal that CHK1 stability is controlled by its steady-state activity during
unchallenged cell proliferation. This autoactivatory mechanism, which depends on ATR and its coactivator ETAA1 and is tightly
associated with CHK1 autophosphorylation at S296, counters CHK1 ubiquitylation and proteasomal degradation, thereby
preventing attenuation of S-phase checkpoint functions and a compromised capacity to respond to RS. Based on these
findings, we propose that steady-state CHK1 activity safeguards its stability to maintain intrinsic checkpoint functions and
ensure genome integrity and cell survival.
Introduction
The genome is constantly exposed to different sources of
harmful agents, both endogenous and exogenous, which can
interfere with the DNA replication machinery, leading to rep-
lication stress (RS) and DNA damage (Zeman and Cimprich,
2014; Saldivar et al., 2017; Te´cher et al., 2017). Mild forms of
RS occur during physiological cell cycle progression, and path-
ological events such as oncogene activation further elevate RS,
promoting genome instability and cancer development (Gaillard
et al., 2015). Markers of persistent RS can be observed in most
cancers and, therefore, defining how mammalian cells deal with
RS and understanding how the RS response is deregulated in
cancer may reveal cancer-specific vulnerabilities that can be
exploited for cancer therapy (Dobbelstein and Sørensen, 2015;
Jackson and Helleday, 2016).
Ataxia telangiectasia and Rad3-related (ATR) is the apical
kinase that responds to RS, and its activity is required to sup-
press RS-associated DNA damage (Yazinski and Zou, 2016;
Blackford and Jackson, 2017). ATR functions are essential even
during normal, unperturbed cell proliferation, and were re-
cently shown to enforce a minimum threshold of replication
before allowing the onset of mitosis (Sørensen and Syljua˚sen,
2012; Eykelenboom et al., 2013; Saldivar et al., 2018). Upon in-
duced RS, ATR is recruited and activated by replication protein
A (RPA) bound to single-stranded DNA (ssDNA). Full kinase
activation depends on activator proteins, and in vertebrates two
ATR activators have been identified, topoisomerase II binding
protein 1 (TOPBP1) and Ewing tumor-associated antigen
1 (ETAA1), which are both recruited to stalled replication forks
through direct interactions with RPA (Bass et al., 2016; Haahr
et al., 2016; Lee et al., 2016). Depletion of TOPBP1 and ETAA1
was shown to be synthetic lethal, suggesting that these two ATR
activating proteins act in parallel and distinct pathways of ATR
activation (Bass et al., 2016; Haahr et al., 2016). Whether these
parallel pathways resemble distinct RS inputs is currently
not known.
Instrumental to the ATR-mediated response to RS is the
downstream effector kinase CHK1, which, by controlling repli-
cation origin firing, delaying cell cycle progression, and stabi-
lizing stalled replication forks, creates a time window to resolve
DNA lesions, and ensures that cells do not enter mitosis when
replication is incomplete (Schmitt et al., 2006; Maya-Mendoza
et al., 2007; Ge and Blow, 2010; Gonza´lez Besteiro and Gottifredi,
2015; Smits and Gillespie, 2015; Toledo et al., 2017). CHK1 loss or
inactivation causes lethality (Liu et al., 2000; Takai et al., 2000),
suggesting that CHK1, similar to ATR, is active during normal
cell cycle progression even in the absence of exogenous RS.
CHK1 activity and stability have been mainly studied upon ex-
cessive RS and in the context of checkpoint adaptation (den
Elzen and O’Connell, 2004; Zhang et al., 2005, 2009; Mailand
et al., 2006; Mamely et al., 2006; Peschiaroli et al., 2006; Collis
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et al., 2019), and the cellular mechanisms that regulate steady-
state CHK1 functions and how they impact replication dynamics
have remained elusive.
Here, we report an autoactivatory loop through which basal
CHK1 activity safeguards its stability in order to maintain in-
trinsic checkpoint functions. Failure to sustain CHK1 auto-
phosphorylation results in its rapid proteasomal degradation,
checkpoint malfunction, and impaired ability to respond to RS.
We propose that this mechanism of intrinsic checkpoint abro-
gation can initiate a vicious cycle and may provide a means to
eliminate checkpoint defective cells from the proliferative pool,
thereby guarding against cellular transformation and cancer
development.
Results and discussion
To evaluate the cellular mechanisms that ensure essential rep-
lication checkpoint functions under unchallenged conditions,
we modulated CHK1 activity in U-2 OS cells by short-term ex-
posure to the small molecule CHK1 inhibitors (CHK1i) UCN-01
and CHIR-124. We monitored basal CHK1 activity by assessing
CHK1 phosphorylation at its residue S296 (pCHK1 S296), an
autophosphorylation site tightly associatedwith CHK1 activation
(Kasahara et al., 2010; Okita et al., 2012; Gonza´lez Besteiro and
Gottifredi, 2015), in parallel to the DNA damage markers
phospho-KAP1 (pKAP1 S824) and phospho-RPA (pRPA S4/8). In
line with previous reports (Syljua˚sen et al., 2005; Shen et al., 2015),
treating cellswith typically used concentrations of UCN-01(300nM)
and CHIR-124 (50 nM) led to a strong induction of DNA damage
(Fig. 1, A and B). Similar results were obtained when we tran-
siently depleted CHK1 by siRNA (Fig. S1 A). To experimentally
uncouple interrogations of checkpoint functions by this es-
sential kinase from the DNA damage caused by complete loss of
its activity, we titrated CHK1i and monitored basal CHK1 ac-
tivity and markers of DNA damage under these conditions. 10-
fold lower concentrations of CHK1i indeed led to reduced CHK1
autophosphorylation at S296 without any signs of DNA damage
(Fig. 1, A and B; and see below). Such conditions therefore
provide an opportunity to assess intrinsic checkpoint functions
and mechanisms of CHK1 regulation without interference from
CHK1i-induced DNA damage. Unexpectedly, we found that
under these conditions of CHK1 inhibition, protein levels of
CHK1 were also markedly decreased (Fig. 1, A and B). This re-
duction in CHK1 protein levels following CHK1 inhibition oc-
curred gradually over time and, upon extended treatment
duration, eventually resulted in DNA damage, similar to CHK1
depletion (Fig. S1 B).
Next, to determine at the single cell level and in a quantita-
tive manner how CHK1 activity impacts its protein levels in the
absence of DNA damage, we established conditions to assess
CHK1 steady-state activity and protein levels in conjunction
with markers of RS and DNA damage signaling by quantitative
image-based cytometry (QIBC; Altmeyer et al., 2013; Toledo
et al., 2013). The observed signals for CHK1 and pCHK1 S296
were specific as revealed by transient CHK1 depletion experi-
ments with and without hydroxyurea (HU)-induced CHK1
activation (Fig. S1, C–E). Based on this approach, cells treated with
a low concentration (30 nM) of CHK1i showed a decrease in
CHK1 activity as measured by pCHK1 S296 staining (Fig. 1 C),
without DNA replication being compromised (Fig. 1 D) and
without significant increase in γH2AX (Fig. 1 E), pRPA, and
pKAP1 (Fig. S1, F and G). As expected, treatment with high
concentrations of CHK1i resulted in catastrophic DNA damage in
S-phase and decreased DNA replication capacity (Fig. 1, D and E;
and Fig. S1, F and G). Moreover, we found that inhibition of
CHK1 basal activity with low doses of CHK1i was coupled to a
clear reduction in CHK1 protein levels (Fig. 1 F). This reduction
was not restricted to S-phase cells but rather occurred
throughout the cell cycle and was evident as early as 30 min
after CHK1i (Fig. 1 G and Fig. S1, H–J). After such short-term
CHK1i, we did not observe a measurable increase in entry into
mitosis, while longer CHK1i (8 h) resulted in accelerated mitotic
entry (Fig. 1 H). Addition of the CDK inhibitor roscovitine re-
verted the accelerated mitotic entry (Fig. 1 H), yet did not rescue
CHK1 levels upon CHK1i (Fig. 1 I), suggesting that the observed
CHK1 loss was unrelated to premature mitotic entry. Reduced
CHK1 levels upon CHK1i were also obtained in a nontransformed
cell line (Fig. S1, K–O). CHK1 mRNA levels, on the other hand,
were unaffected by low-dose CHK1i (Fig. S1 P). Taken together,
these results indicate that CHK1 steady-state activity in un-
stressed conditions controls CHK1 protein levels.
CHK1 activity is regulated by the upstream kinase ATR (Smits
and Gillespie, 2015). ATR depletion by siRNA suppressed CHK1
activity and also decreased total CHK1 protein levels, measured
by both QIBC and Western blot, without adverse effects on DNA
replication (Fig. S2, A–D). To directly test whether steady-state
CHK1 activity promotes its stability, we first measured the half-
life of CHK1 in cells treated or not with CHK1i in the presence of
cycloheximide, an inhibitor of protein synthesis commonly used
for protein half-life measurements. These experiments revealed
that CHK1 was indeed much less stable in CHK1i-treated cells
(with a half-life of ∼2 h) as compared with control cells (Fig. 2
A). Next, we treated cells with CHK1i together with the pro-
teasome inhibitor MG132 to block protein degradation. Reas-
suringly, CHK1 protein levels in CHK1i-treated cells were
rescued almost to control conditions when proteasomal degra-
dation was suppressed (Fig. 2 B). Collectively, these data provide
evidence that steady-state CHK1 activity influences its own
stability by preventing its proteasomal degradation.
To further test this notion, we assessed whether CHK1i would
affect CHK1 ubiquitylation. These experiments revealed that
CHK1 ubiquitylation was indeed elevated in cells treated with
low-dose CHK1i (Fig. 2 C). Previous studies demonstrated that
upon prolonged genotoxic stress treatments, the CUL1- and
CUL4A-containing E3 ubiquitin ligase complexes mediate CHK1
ubiquitylation and proteasomal degradation, and identified
DDB1 as the adapter protein that targets the ubiquitin ligase
complex to CHK1 (Zhang et al., 2005, 2009; Leung-Pineda et al.,
2009; Ma et al., 2018). We therefore assessed whether DDB1
might also control CHK1 degradation upon impaired basal ac-
tivity in the absence of exogenous RS. Indeed, depletion of DDB1
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Figure 1. Steady-state CHK1 activity maintains CHK1 levels in unchallenged conditions. (A)Western blot analysis of asynchronously growing populations
of U-2 OS cells treated with a low (30 nM) or high (300 nM) concentration of CHK1i UCN-01 as indicated. The band intensities were quantified by ImageJ and
are depicted to the right. (B)Western blot analysis of U-2 OS cells treated with a low (5 nM) or high (50 nM) concentration of CHK1i CHIR-124 as indicated. The
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stabilized CHK1 under basal conditions and also restored CHK1
levels from CHK1i-mediated degradation (Fig. 2 D), suggesting
that DDB1 participates in CHK1 degradation upon loss of steady-
state CHK1 activity.
Our findings so far suggest that steady-state activity of CHK1
prevents its ubiquitylation and proteasomal degradation to main-
tain physiological CHK1 levels and to ensure essential CHK1 func-
tions. To directly test the requirement of CHK1 autophosphorylation
band intensities were quantified by ImageJ and are depicted to the right. (C) QICB analysis of U-2 OS cells treated with CHK1i as indicated and stained for
pCHK1 S296, γH2AX, EdU, and DNA content (sample size: 5,092, 5,054, 4,992, and 5,276 cells). (D) Cell cycle–resolved EdU levels from cells in C. (E) γH2AX
levels from the staining in C and D. (F) U-2 OS cells were treated with CHK1i as indicated and stained for CHK1, γH2AX, EdU, and DNA content. QIBC-derived
analysis of CHK1 levels is depicted with median (solid line) and quartiles (dashed lines) indicated (sample size: 3,303, 3,507, and 3,985 cells). (G) Cell
cycle–resolved EdU and CHK1 levels from cells in F. (H) U-2 OS cells were treated with CHK1i (30 nM UCN-01) with or without roscovitine (20 µM) for 30 min
or 8 h as indicated, stained for the mitotic marker phospho-H3 S10 (pH3S10) and DNA content, and analyzed by QIBC with percentages of cells in mitosis
indicated (sample size: 4,916, 5,040, 4,936, 5,152, and 5,025 cells). (I) Western blot analysis of cells treated with CHK1i and roscovitine as in H for 8 h.
Mann–Whitney U test in F. A.U., arbitrary units.
Figure 2. CHK1 inhibition accelerates CHK1 proteasomal degradation. (A) U-2 OS cells treated or not with low-dose CHK1i were exposed to cycloheximide
(CHX), collected at indicated time points, and immunoblotted with CHK1- and KAP1-recognizing antibodies to assess CHK1 half-life with and without CHK1i.
(B) U-2 OS cells were exposed to low-dose CHK1i and the proteasome inhibitor MG132 for 2 h as indicated and stained for CHK1. QIBC-derived levels of CHK1
are shown with median (solid line) and quartiles (dashed lines) indicated (sample size: 3,915, 3,938, 3,594, and 3,772 cells). (C) U-2 OS cells were transfected
with a ubiquitin-FLAG (Ubi-FLAG) expressing plasmid, and treated with MG132 and low-dose CHK1i for 4 h as indicated, and endogenous CHK1 was im-
munoprecipitated with a CHK1-recognizing antibody. Immunoprecipitates were blotted with FLAG antibody to detect ubiquitylated CHK1. IP, immunopre-
cipitation; WCE, whole cell extract. (D) U-2 OS cells were transfected with negative control siRNA or siRNA against DDB1 for 48 h, treated with low-dose CHK1i
and MG132 for 4 h, and blotted with CHK1, DDB1, and PCNA antibodies. (E) U-2 OS cells expressing either WT CHK1-HA, CHK1-HA S296A, or CHK1-HA D130A
upon doxycycline (Dox) addition for 24 h were analyzed by QIBC for their HA-signal (sample size: 8,001, 8,118, 7,042, 7,718, 8,396, and 8,695 cells). (F) In the
same cells from E, pCHK1 S296 was analyzed. (G)Western blot analysis of U-2 OS expressing WT CHK1-HA, CHK1-HA S296A, or CHK1-HA D130A treated with
CHX for 1 h as indicated. A representative Western blot is shown together with quantifications of relative HA intensities from Western blots of three inde-
pendent experiments with means ± SD indicated. Mann–Whitney U test in B, unpaired t test in G. A.U., arbitrary units.
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for its stability, we generated stable cell lines expressing in an in-
ducible manner either WT CHK1, a CHK1 S296A mutant, or a cat-
alytically inactive CHK1 D130A mutant (Chen et al., 2000). The
three proteins, carrying an HA tag for detection, were expressed at
comparable levels upon induction (Fig. 2 E). Reassuringly, only WT
CHK1 expression resulted in an increase in pCHK1 S296, while both
the S296A and the D130A mutants were defective in this modifi-
cation (Fig. 2 F). Bothmutants were consistently less stable than the
WT counterpart, providing evidence that loss of catalytic activity
and S296 autophosphorylation promote CHK1 turnover (Fig. 2 G).
We therefore conclude that CHK1 autophosphorylation is needed to
maintain its stability in unperturbed conditions.
Given the essential genome maintenance function of CHK1,
we aimed to identify upstream factors, which would modulate
CHK1 steady-state activity and stability in unchallenged con-
ditions. To this end, we performed a high-content microscopy-
based screen using a targeted, custom-designed siRNA library
comprising genes with known roles in genome integrity main-
tenance and ATR/CHK1 regulation and assessed CHK1 levels and
γH2AX. Among the factors whose depletion led to lower CHK1
levels, we identified Ataxin-3 (Fig. 3 A and Table S1), a deubi-
quitinase that was previously shown to suppress CHK1 ubiq-
uitylation and proteasomal degradation (Tu et al., 2017).
Interestingly, we also identified ETAA1 as a putative positive
regulator of CHK1 levels (Fig. 3 A). ETAA1 is an ATR activator,
which was recently shown to regulate the S/G2 transition in
normally proliferating cells (Saldivar et al., 2018). We thus
considered the possibility that ETAA1 might control CHK1 levels
in unchallenged cells. We validated the screen results using
different siRNAs against ETAA1 and assessing CHK1 levels by
Western blot (Fig. 3 B), and confirmed that CHK1 levels were
reduced upon ETAA1 depletion in different transformed and
nontransformed cell lines (Fig. S2, E and F). Importantly, the
half-life of CHK1 was also reduced in multiple cell lines upon
ETAA1 depletion, supporting a role of ETAA1 in maintaining
CHK1 protein stability (Fig. S2, G–I). We next tested the possi-
bility that ETAA1 might regulate CHK1 levels by promoting its
basal activation state in unchallenged conditions. Indeed,
steady-state pCHK1 S296 was reduced in ETAA1-depleted cells,
while RS-induced CHK1 activation was only mildly impaired
(Fig. 3 C and Fig. S2, J and K). In contrast, depletion of the second
known ATR activator protein, TOPBP1, which did not score in
our initial screen (Fig. 3 A), only mildly affected CHK1 levels, its
half-life, and steady-state activity, despite the fact that it
strongly reduced CHK1 activation after exogenous RS (Fig. S2,
L–O). The reduced CHK1 protein levels upon ETAA1 depletion
were partly restored by DDB1 codepletion (Fig. 3 D and Fig. S2 P),
indicating that by ensuring CHK1 activity, ETAA1 abrogates
DDB1-mediated CHK1 proteasomal degradation. Taken together,
our results suggest that impaired basal CHK1 activity, either at
the level of CHK1 activation itself or at the level of upstream
signaling through ATR/ETAA1 (and, under unchallenged con-
ditions, to a lesser extent through ATR/TOPBP1), leads to rapid
proteasomal degradation of CHK1 and reduces CHK1 levels.
Finally, we asked what the cellular consequences are of im-
paired CHK1 autoactivation and destabilization. Loss of CHK1
resulted in increased levels of the RS sensor and negative cell cycle
regulator p21 before DNA damage signaling (Fig. S3, A and B),
Figure 3. A high-content microscopy-based
screen identifies the ATR activator ETAA1 as
a novel regulator of CHK1 stability. (A) Tar-
geted siRNA screen for modulators of CHK1
levels. Three independent siRNAs were used
against each target gene for 48 h, the results
were averaged, and z-scores according to CHK1
levels are shown. On average, 4,300 cells were
analyzed by QIBC for each gene. (B) Western
blot analysis of pCHK1 S296 and total CHK1 levels
in U-2 OS cells transfected for 48 h with three in-
dependent siRNAs against ETAA1. (C) U-2 OS
cells were transfected with siETAA1 (A) for 48 h,
treated with CPT (1 µM) for 1 h, and stained for
pCHK1 S296. QIBC-derived levels of pCHK1
S296 are shown with median (solid line) and
quartiles (dashed lines) indicated (sample size:
2,599, 4,791, 3,210, and 5,009 cells). (D) U-2 OS
cells were transfected with siETAA1 (A) and
siDDB1 for 48 h as indicated and stained for
CHK1. QIBC-derived levels of CHK1 are shown
with median (solid line) and quartiles (dashed
lines) indicated (sample size: 6,819, 6,592, 6,723,
and 6,772 cells). Mann–Whitney U test in C and
D. A.U., arbitrary units.
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Figure 4. CHK1 degradation upon impaired steady-state activity sensitizes to RS. (A) U-2 OS cells were treated as indicated for 4 h with low-dose CHK1i,
2mM HU, or both, and stained for γH2AX, pCHK1 S296 and DNA content. QIBC-derived γH2AX profiles are shown (sample size: 4,896, 5,153, 5,005, and 5,187
cells). (B) pCHK1 S296 profiles from the staining in A are shown. (C) Western blot analysis of DNA damage markers in cells treated as indicated for 4 h with
low-dose CHK1i, 2 mM HU, or both. (D) U-2 OS cells were treated with low-dose CHK1i for 2 h, the inhibitor was washed out, and the cells were then treated
with 2 mM HU for an additional 2 h. Cells were stained for γH2AX, pCHK1 S296, and DNA content. QIBC-derived γH2AX profiles are shown (sample size: 5,388,
5,187, 4,190, 4,831, and 5,060 cells). (E) pCHK1 S296 profiles from the staining in D are shown. (F) Western blot analysis of DNA damage markers in cells
treated as in D and E. (G) U-2 OS cells were treated with CDC7i to block origin firing in the presence or absence of low-dose CHK1i for 4 h, the drugs were
removed, and cells were then exposed to 2 mM HU for 2 h. Cells were stained for γH2AX, pCHK1 S296, and DNA content. QIBC-derived γH2AX profiles are
shown (sample size: 3,147, 3,177, 3,757, 2,656, and 3,524 cells). (H) pCHK1 S296 profiles from the staining in G are shown. (I) Western blot analysis of DNA
Michelena et al. Journal of Cell Biology 6
Basal CHK1 activity maintains its stability https://doi.org/10.1083/jcb.201902085
consistent with elevated RS upon checkpoint impairment. In
agreement, short-term inhibition of CHK1 (using the low-dose
CHK1i that on its own does not cause immediate DNA damage)
greatly sensitized cells to HU, but only moderately affected the
response to camptothecin (CPT; Fig. 4, A–C; and Fig. S3, C and D).
To uncouple CHK1 inhibition from CHK1i-induced CHK1
destabilization, we treated cells for 2 h with CHK1i, and then
washed out the drug before exposing cells to HU (Fig. 4, D–F).
This resulted in reduced CHK1 levels (Fig. 4 F), yet largely re-
stored HU-induced activation of the remaining CHK1 (Fig. 4 E).
Also in these conditions, the cells that had been exposed to
CHK1i were hypersensitive to HU-induced RS (Fig. 4, D and F).
Moreover, to further dissociate the effect of CHK1i-induced
CHK1 degradation from CHK1i-induced origin firing, we com-
bined the CHK1i pulse with CDC7 inhibition to block activation
of new origins and thereby abrogate this branch of CHK1i
functions (Fig. S3, E–G). CHK1i-exposed cells were hypersensi-
tive to acute RS also in these conditions, despite the fact that the
remaining CHK1 pool was efficiently activated by HU (Fig. 4,
G–I; and Fig. S3, H–K). The sensitization was milder compared
with the conditions without CDC7i, consistent with the notion
that hyperactivation of origin firing by CHK1i is a major con-
tributor to RS sensitivity. Collectively, these experiments sug-
gest that lowered CHK1 levels, upon impaired steady-state CHK1
activity and the ensuing CHK1 degradation, are insufficient to
properly maintain S-phase checkpoint functions. Keeping cells
exposed to CDC7i during the complete duration of the experi-
ment largely rescued this effect (Fig. 4, J and K), indicating that
unscheduled activation of replication origins upon lowered
CHK1 levels drive RS sensitivity. These findings are in agreement
with previous studies demonstrating CHK1 haploinsufficiency
(Lam et al., 2004; Boles et al., 2010) and suggest that reductions
in CHK1 levels, even during unperturbed DNA replication, affect
the replication program and can sensitize cells to RS. In sum-
mary, we therefore propose that a failure to maintain an au-
toactivatory loop of basal CHK1 activity and stability turns this
loop into a vicious cycle of CHK1 destabilization, impaired in-
trinsic S-phase checkpoint functions, accumulation of RS and
DNA damage, and eventually elimination of affected cells from
the proliferative pool (Fig. 5).
Using controlled conditions of CHK1 inhibition allowed us to
unveil an autoactivatory mechanism by which cells ensure
maintenance functions of this essential kinase during unper-
turbed cell cycle progression. Our results show that reduced
CHK1 activity does not result in immediate DNA damage. Rather,
the inability to promote its own phosphorylation leads to CHK1
destabilization and gradual decrease of CHK1 levels. We thus
propose that an autoactivatory mechanism prevents a negative
circuit of CHK1 degradation, loss of intrinsic checkpoint func-
tions, compromised capability to respond to RS, and decreased
replication capacity.
Loss of checkpoint activity has previously been shown to
promote CHK1 protein destabilization (Collis et al., 2007; Lin
et al., 2014). However, under conditions of complete loss of
checkpoint function, CHK1 destabilization co-occurs with and
therefore cannot be easily uncoupled from the associated DNA
damage. Indeed, exogenous genotoxic assaults can target CHK1
for proteasomal degradation as a means to actively terminate
checkpoint signaling and allow cells to resume cell cycle pro-
gression (Zhang et al., 2005). Different from such a scenario of
checkpoint termination, our results illustrate that during nor-
mal cell proliferation and in the absence of DNA damage, a
threshold of basal CHK1 activity is actually required to maintain
its stability. In line with this notion, we envision a broad spec-
trum of conditions in which CHK1 activation, e.g., by defects in
the upstream signaling, is impaired and in which reduced CHK1
stability will render cells hypersensitive to RS treatments.
The molecular signals needed to maintain the CHK1 au-
toactivatory loop during unperturbed cell proliferation remain
poorly defined and are a subject for further research. Somewhat
surprisingly, our cell cycle–resolved single cell analyses of CHK1
basal activity and stability suggest that this regulatory circuit is
not confined to the S-phase, but instead operates throughout the
cell cycle. We thus reason that DNA replication might not be the
sole cellular signal that maintains CHK1 activity and stability.
RPA, which functions as a key sensor of ssDNA and creates a
platform for ATR/CHK1 activation, was previously shown to bind
to transcriptionally active gene regulatory elements indepen-
dently of the cell cycle position, suggesting that ssDNA is present
at sites of transcription (Sikorski et al., 2011; Nguyen et al., 2017;
Zhang et al., 2017). It is thus tempting to speculate that tran-
scriptional activity could play a role in promoting basal ATR/CHK1
activity. Further work will be needed to mechanistically dissect
how alterations in transcription or mRNA biogenesis affect in-
trinsic S-phase checkpoint functions in contexts beyond DNA
replication. Interestingly, the ability of ETAA1 to bind directly to
RPA distinguishes it from TOPBP1, which requires a free 59 end at
ssDNA–dsDNA junctions, e.g., upon DNA breakage-induced DNA
end resection, for recruitment via the MRE11-RAD50-NBS1 and
9-1-1 complexes (Saldivar et al., 2017). Therefore, ETAA1 and
TOPBP1 likely have both overlapping as well as distinct func-
tions in S-phase checkpoint control, with ETAA1 promoting
steady-state ATR/CHK1 activity and controlling origin activa-
tion in unchallenged conditions and TOPBP1 playing a more
dominant role upon acute and more severe RS and when cells
experience DNA damage during S-phase progression.
Impaired CHK1 function, regardless of the upstream defect,
comes with the risk of deregulated cell cycle control, repli-
cation problems, and RS-associated DNA damage. We suggest
that CHK1 destabilization by proteasomal degradation when
its basal activity cannot be maintained might be a common
outcome of multiple settings of checkpoint malfunction and
damage markers in cells treated as in G and H. (J) U-2 OS cells were treated with CDC7i in the presence or absence of low-dose CHK1i for 4 h, the drugs were
removed, and cells were then exposed to 0.5 mM HU for 2 h with or without CDC7i. Cells were stained for γH2AX and DNA content. QIBC-derived γH2AX
profiles are shown (sample size: 5,361, 4,888, 4,902, and 4,619 cells), and γH2AX levels from cells in S-phase are additionally shown as box plots with white
lines indicating the median. (K) Western blot analysis of DNA damage markers in cells treated as in J. Mann–Whitney U test in J. A.U., arbitrary units.
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that it provides a general safeguard mechanism to eliminate
severely compromised cells with persistently impaired
checkpoint function from the proliferative cell pool. Given
the frequent down-regulation of p53 and p21 in cancer, this
safeguard mechanism might become deactivated during car-
cinogenesis, thus allowing checkpoint-impaired cells to con-
tinue proliferate and accumulate mutations. Knowing the
cellular thresholds at which ATR and CHK1 inhibitors lead to
CHK1 destabilization without causing massive DNA damage in
S-phase might be of help to better define the therapeutic
windows for these essential protein kinase inhibitors.
Materials and methods
Cell culture, drug treatments, and 5-ethynyl-29-desoxyuridine
(EdU) labeling
Cells were grown in a sterile cell culture environment and rou-
tinely tested for mycoplasma contamination. Human U-2 OS
cells, hTERT-RPE1 cells, and HeLa cells (all of female
origin) were grown under standard cell culture conditions
(humidified atmosphere, 5% CO2) in DMEM containing 10%
FBS (GIBCO) and penicillin-streptomycin antibiotics. U-2 OS
TetOn cells (kindly provided by A. Zubiaga) stably expressing
CHK1 were generated by transfection of pTRE2hyg2-HA
containing the CHK1 sequence (WT, S296A, or D130A). In-
duction of CHK1 expression was achieved by doxycycline
treatment (1,000 ng/ml). All cultured cells were routinely
assessed by QIBC for proper proliferation and absence of ab-
normal stress signals using cell cycle–resolved profiles of
CyclinA, CyclinB, 53BP1, and RPA foci, as well as nuclear
morphology and EdU incorporation as readouts. Plasmid
transfections were performed with Lipofectamine 3000
(Thermo Fisher Scientific) according to the manufacturer’s
recommendations. For pulsed EdU (Thermo Fisher Scientific)
incorporation, cells were incubated for 20 min in medium
containing 10 µM EdU. The Click-iT EdU Alexa Fluor Imaging
Kit (Thermo Fisher Scientific) was used for EdU detection.
Unless stated otherwise, the following compounds were used at
the indicated final concentrations: UCN-01 (30–300 nM;
U6508; Sigma-Aldrich), MG132 (10 µM; M7449; Sigma-
Aldrich), cycloheximide (50 µM; C7698; Sigma-Aldrich), CHIR-
124 (5–50 nM; S2683; Selleckchem), CPT (50 nM to 1 µM;
S1288; Selleckchem), HU (0.1–2 mM; H8627; Sigma-Aldrich),
CDC7i PHA-767491 (20 µM; S2742; Selleckchem), and rosco-
vitine (20 µM; S1153; Selleckchem). Irradiation was per-
formed with a Faxitron Cabinet x-ray System Model RX-650.
siRNA transfections
siRNA transfections were performed for 24–72 h as indicated
with Ambion Silencer Select siRNAs using Lipofectamine
RNAiMAX (Thermo Fisher Scientific). The following Ambion
Silencer Select siRNAs were used: CHK1 (s502): 59-GACACGAUU
CUUUACCAAA-39; DDB1 (s3981): 59-GAGAUUGCUCGAGACUUU
A-39; ETAA1 #A (s29020): 59-GUAAAACCAGUGUUAGUAA-39;
ETAA1 #B (s29019): 59-GACUAGUGCAUCAAAAGUA-39; ETAA1
#C (s29018): 59-GCAUGUCAUCAAUUAGAUA-39; ATR (s536): 59-
UUGUAGAAAUGGAUACUGA-39; TOPBP1 (s21824): 59-GCAGAA
CUGUUGCGGAUUA-39.
Unless stated otherwise, ETAA1 #A (s29020) was used for
ETAA1 depletions. Negative Silencer Select control Neg1 from
Ambion was used as nontargeting control and is abbreviated
siCon in the figures. For individual siRNA transfections, a final
siRNA concentration of 25 nMwas used unless stated otherwise.
CHK1 depletion was performed at a final siRNA concentration of
0.2 nM. When several siRNAs were combined, the final siRNA
concentration was identical for all conditions within one ex-
periment. The siRNA-based screen was performed by reverse-
transfection of U-2 OS cells cultured in CELLSTAR 96-well plates
(Greiner Bio-One) with Ambion Silencer Select siRNAs at a final
concentration of 5 nM using HiPerFect (Qiagen) reagent.
RNA extraction and quantitative PCR (qPCR)
RNA was purified with TRIzol reagent (Life Technologies). RNA
was primed with random hexamers (11034731001; Roche) and
reverse-transcribed to cDNA using a MultiScribe Reverse tran-
scription (4311235; Thermo Fisher Scientific). qPCR was per-
formed with KAPA SYBR FAST qPCR Kit (KAPA Biosystems) on
a Rotor Gene Q system (Qiagen). Samples were run in triplicates
and normalized to EIF2C2, and results are depicted as relative
fold changes. The following primer pairs were used: CHK1 for-
ward: 59-AAAGGGATAACCTCAAAATCTCAGACT-39; CHK1 re-
verse: 59-ATACCGAAATACTGTTGCCAAGC-39; EIF2C2 forward:
59-GTCCCTTTTGAGACGATCCAG-39; EIF2C2 reverse: 59-AGC
CAAACCACACTTCTCG-39.
Immunochemical methods
Proteins were resolved by SDS-PAGE and transferred onto pol-
yvinylidene fluoride membranes. Membranes were blocked
with PBS-Tween 20 (0.01%) containing 5% milk powder for 1 h
at room temperature. Primary antibodies in blocking solution
were applied overnight at 4°C. The following primary antibodies
were used for Western blot analysis: CHK1 (1:1,000; rabbit;
ab40866; Abcam), CHK1 phospho S296 (1:500; rabbit; ab79758;
Figure 5. Working model of CHK1 regulation. CHK1 activity
safeguards CHK1 stability during normal cell proliferation. This
autoactivation cycle can turn into a vicious cycle of CHK1 de-
stabilization upon impaired CHK1 activity, which leads to
compromised checkpoint functions, RS sensitivity, and even-
tually DNA damage and cell cycle exit.
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Abcam), CHK1 phospho S317 (1:500; rabbit; 2344; Cell Signaling),
CHK1 phospho S345 (1:500; rabbit; 2348; Cell Signaling), ETAA1
(1:500; rabbit; ab122245; Abcam), DDB1 (1:2,000; rabbit;
ab109027; Abcam), TOPBP1 (1:1,000; rabbit; ab2402; Abcam),
RPA32 phospho S4/8 (1:500; rabbit; A300-245A; Bethyl), KAP1
phospho S824 (1:500; rabbit; ab70369; Abcam), KAP1 (1:1,000;
rabbit; A300-274A; Bethyl), PCNA (1:1,000; mouse; sc-56; Santa
Cruz), tubulin (1:2,000; mouse; T6199; Sigma-Aldrich), and HA
(1:500; mouse; 901513; Biolegend). Secondary horseradish
peroxidase–coupled antibodies (Vector Laboratories and
Thermo Fisher Scientific) were applied for 1 h at room tem-
perature in PBS-Tween 20 (0.01%) containing 1% milk powder
before detection by ECL-based chemiluminescence.
Immunostaining
Cells were grown on sterile 12-mm glass coverslips, fixed in 3%
formaldehyde in PBS for 15 min at room temperature, washed
once in PBS, permeabilized for 5 min at room temperature in
PBS supplemented with 0.2% Triton X-100 (Sigma-Aldrich), and
washed twice in PBS. All primary antibodies (see below for
specifications) and secondary antibodies (Alexa fluorophores;
Life Technologies) were diluted in filtered DMEM containing
10% FBS and 0.02% sodium azide. Antibody incubations were
performed for 1–2 h at room temperature. After antibody in-
cubations, coverslips were washed once with PBS and incubated
for 10 min with PBS containing DAPI (0.5 µg/ml) at room
temperature to stain DNA. Following three washing steps in
PBS, coverslips were briefly washed with distilled water and
mounted on 6 µl Mowiol-based mounting media. The following
primary antibodies were used for immunostaining: CHK1 (1:500;
rabbit; ab40866; Abcam), CHK1 phospho S296 (1:500; rabbit;
ab79758; Abcam), H2AX phospho S139 (1:1,000; mouse; 613401;
Biolegend), KAP1 phospho S824 (1:500; rabbit; ab70369; Abcam),
RPA32 phospho S4/8 (1:500; rabbit; A300-245A; Bethyl), p21
(1:100; rabbit; sc-756; Santa Cruz), HA (1:500; mouse; 901513;
Biolegend), and pH3S10 (rabbit; ab5176; Abcam).
QIBC
Automated multichannel wide-field microscopy for QIBC was
performed on an Olympus ScanR Screening System equipped with
an inverted motorized Olympus IX83 microscope, a motorized
stage, infrared-laser hardware autofocus, a fast emission filter
wheel with single band emission filters, and a digital monochrome
Hamamatsu ORCA-FLASH 4.0 V2 sCMOS camera (2,048 × 2,048
pixels, 12-bit dynamics). For each condition, image information of
large cohorts of cells (typically at least 500 cells for the UPLSAPO
40× objective [NA 0.9], at least 2,000 cells for the UPLSAPO 20×
objective [NA 0.75], and at least 5,000 cells for the UPLSAPO 10×
[NA 0.4] and UPLSAPO 4× [NA 0.16] objectives) was acquired
under nonsaturating conditions at a single autofocus-directed
z-position. Identical settings were applied to all samples within
one experiment. Images were analyzed with the inbuilt Olympus
ScanR Image Analysis Software Version 3.0.0, a dynamic back-
ground correction was applied, and nuclei segmentation was per-
formed using an integrated intensity-based object detection
module based on the DAPI signal. All downstream analyses were
focused on properly detected interphase nuclei containing a 2C-4C
DNA content as measured by total and mean DAPI intensities.
Unless stated otherwise, mitotic cells with condensed chromo-
somes based on high mean DAPI were excluded from the quanti-
fications. Fluorescence intensities were quantified and are depicted
as arbitrary units. Color-coded scatter plots of asynchronous cell
populations were generated with Spotfire data visualization soft-
ware (TIBCO) and GraphPad Prism 8.0 for depicting the data as
violin plots. Within one experiment, similar cell numbers were
compared for the different conditions. Representative scatter plots
and quantifications of independent experiments, typically con-
taining several thousand cells each, are shown.
Coimmunoprecipitation
To assess ubiquitin levels of CHK1, cells transfected with a
plasmid expressing Flag-ubiquitin were collected in RIPA buffer
(50 mM Tris, pH 8, 150 mM NaCl, 1% Igepal CA-630, 0.1% SDS,
and 0.1% Na-deoxycholic acid) supplemented with 2 mM MgCl2,
25 U/ml benzonase (71206–3; Merck), 1× protease inhibitor
cocktail (cOmplete; Roche), 1× phosphatase inhibitor cocktail
(PhosSTOP; Roche), and 10 mM N-ethylmaleimide. 10% of the
volume was kept for input controls. 600 µg of protein was sub-
jected to immunoprecipitation for 3 h at 4°C using CHK1 antibody
(1 µg per sample; rabbit; ab40866; Abcam) coupled to 15 µl of
equilibrated beads (Protein G Sepharose 4 Fast Flow; 17-0618-01;
GE). Precipitates were washed three times with immunoprecip-
itation buffer, separated on a 10% SDS–polyacrylamide gel, and
analyzed by immunoblot.
DNA fiber analysis
Cells were pulse-labeled during the last hour of the indicated
treatments with 38 µM CldU (Sigma-Aldrich) and 340 µM IdU
(European Pharmacopoeia) for 30 min each. Cells were col-
lected and resuspended in PBS at 3 × 105 cells per ml. The
labeled cells were diluted 2:1 (vol/vol) with unlabeled cells,
and 3 µl of cell suspension were mixed with 7 µl of lysis buffer
(200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and 0.5% [wt/vol]
SDS) on a glass slide. After 9 min, the slide was tilted to 15–45°,
and the resulting DNA spreads were air-dried and fixed in
methanol/acetic acid (3:1) solution overnight at 4°C. The fibers
were denatured with 2.5 M HCl for 60 min, washed several
times with PBS to neutralize the pH, and blocked with 0.1%
Tween 20 in 2% BSA/PBS for 40 min. The newly replicated
CldU and IdU tracks were labeled for 2.5 h at room tempera-
ture with anti-BrdU antibodies recognizing CldU (1:400; rat;
ab6326; Abcam) and IdU (1:80; mouse; 347580 B44; BD), fol-
lowed by a 1.5-h incubation with secondary antibodies at room
temperature in the dark: anti-mouse Alexa Fluor 488 (1:250;
A11001; Invitrogen) and anti-rat Cy3 (1:250, 712-166-153;
Jackson ImmunoResearch Laboratories). Fibers were visual-
ized on a Leica DMI 6000 inverted microscope using an HCX
Plan APO DIC 63× oil objective (1.4–0.6 NA) and analyzed
using Fiji. At least 100 fibers were analyzed per replicate
condition. Origins of replication initiating during the first
pulse with CIdU (detected in red) and extending in both di-
rections from the point of initiation as determined by the
subsequent bidirectional incorporation of ldU (detected in
green) were scored from at least 100 fibers per condition in
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technical duplicates from two independent experiments, and
the results are depicted as means ± SD.
Statistical analysis
QIBC-derived quantifications are depicted as violin plots with
median (solid line) and quartiles (dashed lines) indicated, or as
box plots of the interquartile range with medians indicated
(white lines), whiskers denoting the 1.5 × interquartile range
range, and outliers shown as individual data points. DNA fiber
length measurements are shown as scatter plots with means ±
SD. Replication initiation events are depicted as means ± SD, and
individual data points are shown in the same graph. qPCR data
are presented as means ± SD. The Mann–Whitney U test was
used to compare QIBC data and replication fork speed meas-
urements. The unpaired t test was used for qPCR, Western blot,
and origin firing data. GraphPad Prism Version 8.0 was used for
all statistical analyses; P < 0.05 was considered significant and
P ≥ 0.05 was considered not significant.
Online supplemental material
Fig. S1 contains additional data panels on CHK1 steady-state
activity regulating CHK1 stability and is mainly related to
Fig. 1. Fig. S2 contains additional data panels on upstream reg-
ulators of CHK1 activity and stability and is mainly related to
Figs. 2 and 3. Fig. S3 contains additional data panels on con-
sequences of CHK1 degradation upon impaired steady-state ac-
tivity and is mainly related to Fig. 4. Table S1 provides individual
z-scores for CHK1 levels upon siRNA-mediated knockdowns
related to the screen results depicted in Fig. 3 A.
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